questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Hémoprotéines
Cytochromes
Cytochrome P-450 enzyme system
Famille-2 de cytochromes P450
Limonène hydroxylases
Limonène hydroxylases : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Déficience enzymatique
Tests génétiques
Tests biochimiques
Activité enzymatique
Symptômes
Dysfonction enzymatique
Tests génétiques
Mutations
Symptômes
5
Troubles métaboliques
Réactions allergiques
Éruptions cutanées
Hypersensibilité
Troubles neurologiques
Symptômes
Prévention
5
Alimentation équilibrée
Nutriments
Tests génétiques
Surveillance précoce
Environnement de travail
Exposition
Traitements
5
Traitements symptomatiques
Modifications diététiques
Thérapie génique
Recherche
Thérapies alternatives
Gestion des symptômes
Complications
5
Complications métaboliques
Réactions allergiques
Risques à long terme
Maladies chroniques
Complications neurologiques
Cas rares
Facteurs de risque
5
Antécédents familiaux
Expositions environnementales
Facteurs environnementaux
Produits chimiques
Mode de vie
Complications
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Limonène hydroxylases : Questions médicales les plus fréquentes",
"headline": "Limonène hydroxylases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Limonène hydroxylases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-17",
"dateModified": "2025-04-12",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Limonène hydroxylases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Famille-2 de cytochromes P450",
"url": "https://questionsmedicales.fr/mesh/D000072467",
"about": {
"@type": "MedicalCondition",
"name": "Famille-2 de cytochromes P450",
"code": {
"@type": "MedicalCode",
"code": "D000072467",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.422.220.453.491"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Cytochrome P-450 CYP2C9",
"alternateName": "Cytochrome P-450 CYP2C9",
"url": "https://questionsmedicales.fr/mesh/D065729",
"about": {
"@type": "MedicalCondition",
"name": "Cytochrome P-450 CYP2C9",
"code": {
"@type": "MedicalCode",
"code": "D065729",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.422.220.453.491.500.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Cytochrome P-450 CYP2C19",
"alternateName": "Cytochrome P-450 CYP2C19",
"url": "https://questionsmedicales.fr/mesh/D065731",
"about": {
"@type": "MedicalCondition",
"name": "Cytochrome P-450 CYP2C19",
"code": {
"@type": "MedicalCode",
"code": "D065731",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.422.220.453.491.500.700"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Limonène hydroxylases",
"alternateName": "Limonene Hydroxylases",
"code": {
"@type": "MedicalCode",
"code": "D065730",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Sasa Liu",
"url": "https://questionsmedicales.fr/author/Sasa%20Liu",
"affiliation": {
"@type": "Organization",
"name": "College of Enology, Northwest A&F University, Yangling, Shaanxi, 712100, People's Republic of China."
}
},
{
"@type": "Person",
"name": "Yuyao Ren",
"url": "https://questionsmedicales.fr/author/Yuyao%20Ren",
"affiliation": {
"@type": "Organization",
"name": "Laboratory of Biotechnology, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 457 Zhongshan Road, Dalian, 116023, People's Republic of China."
}
},
{
"@type": "Person",
"name": "Guojie Jin",
"url": "https://questionsmedicales.fr/author/Guojie%20Jin",
"affiliation": {
"@type": "Organization",
"name": "College of Enology, Northwest A&F University, Yangling, Shaanxi, 712100, People's Republic of China."
}
},
{
"@type": "Person",
"name": "Xiaobing Yang",
"url": "https://questionsmedicales.fr/author/Xiaobing%20Yang",
"affiliation": {
"@type": "Organization",
"name": "College of Enology, Northwest A&F University, Yangling, Shaanxi, 712100, People's Republic of China. yangxb@nwafu.edu.cn."
}
},
{
"@type": "Person",
"name": "Elham Zarenezhad",
"url": "https://questionsmedicales.fr/author/Elham%20Zarenezhad",
"affiliation": {
"@type": "Organization",
"name": "Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "No Association of Multiple Sclerosis with",
"datePublished": "2023-07-09",
"url": "https://questionsmedicales.fr/article/37511014",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms241411254"
}
},
{
"@type": "ScholarlyArticle",
"name": "The immunology of multiple sclerosis.",
"datePublished": "2022-05-04",
"url": "https://questionsmedicales.fr/article/35508809",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41577-022-00718-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Ocrelizumab for multiple sclerosis.",
"datePublished": "2022-05-18",
"url": "https://questionsmedicales.fr/article/35583174",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/14651858.CD013247.pub2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Alemtuzumab for multiple sclerosis.",
"datePublished": "2023-06-05",
"url": "https://questionsmedicales.fr/article/37272540",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/14651858.CD011203.pub3"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Multiple sclerosis treatments].",
"datePublished": "2023-03-23",
"url": "https://questionsmedicales.fr/article/37037639",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.soin.2023.02.005"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Hémoprotéines",
"item": "https://questionsmedicales.fr/mesh/D006420"
},
{
"@type": "ListItem",
"position": 5,
"name": "Cytochromes",
"item": "https://questionsmedicales.fr/mesh/D003580"
},
{
"@type": "ListItem",
"position": 6,
"name": "Cytochrome P-450 enzyme system",
"item": "https://questionsmedicales.fr/mesh/D003577"
},
{
"@type": "ListItem",
"position": 7,
"name": "Famille-2 de cytochromes P450",
"item": "https://questionsmedicales.fr/mesh/D000072467"
},
{
"@type": "ListItem",
"position": 8,
"name": "Limonène hydroxylases",
"item": "https://questionsmedicales.fr/mesh/D065730"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Limonène hydroxylases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Limonène hydroxylases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Limonène hydroxylases",
"description": "Comment diagnostiquer une déficience en limonène hydroxylases ?\nQuels tests sont utilisés pour évaluer l'activité des limonène hydroxylases ?\nLes symptômes peuvent-ils indiquer un problème avec les limonène hydroxylases ?\nY a-t-il des biomarqueurs associés aux limonène hydroxylases ?\nComment les tests génétiques aident-ils au diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D065730?mesh_terms=Multiple+Sclerosis#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Limonène hydroxylases",
"description": "Quels symptômes sont liés à une déficience en limonène hydroxylases ?\nLes symptômes varient-ils selon les individus ?\nPeut-on observer des symptômes cutanés ?\nLes symptômes respiratoires sont-ils fréquents ?\nY a-t-il des symptômes neurologiques associés ?",
"url": "https://questionsmedicales.fr/mesh/D065730?mesh_terms=Multiple+Sclerosis#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Limonène hydroxylases",
"description": "Peut-on prévenir les troubles liés aux limonène hydroxylases ?\nY a-t-il des mesures diététiques préventives ?\nLes tests génétiques peuvent-ils aider à la prévention ?\nL'éducation sur les allergies est-elle importante ?\nLes environnements de travail peuvent-ils influencer la santé ?",
"url": "https://questionsmedicales.fr/mesh/D065730?mesh_terms=Multiple+Sclerosis#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Limonène hydroxylases",
"description": "Quels traitements sont disponibles pour les troubles liés aux limonène hydroxylases ?\nLa thérapie génique est-elle une option ?\nDes médicaments spécifiques existent-ils ?\nComment la nutrition peut-elle aider ?\nLes traitements alternatifs sont-ils efficaces ?",
"url": "https://questionsmedicales.fr/mesh/D065730?mesh_terms=Multiple+Sclerosis#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Limonène hydroxylases",
"description": "Quelles complications peuvent survenir avec une déficience en limonène hydroxylases ?\nLes complications sont-elles réversibles ?\nY a-t-il des risques à long terme ?\nLes complications affectent-elles la qualité de vie ?\nDes complications neurologiques sont-elles possibles ?",
"url": "https://questionsmedicales.fr/mesh/D065730?mesh_terms=Multiple+Sclerosis#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Limonène hydroxylases",
"description": "Quels sont les facteurs de risque pour les troubles enzymatiques ?\nL'âge influence-t-il le risque de déficience ?\nLes allergies augmentent-elles le risque ?\nY a-t-il des facteurs environnementaux à considérer ?\nLe mode de vie joue-t-il un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D065730?mesh_terms=Multiple+Sclerosis#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en limonène hydroxylases ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques et des analyses génétiques peuvent être réalisés."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité des limonène hydroxylases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests biochimiques mesurant l'activité enzymatique dans des échantillons biologiques."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils indiquer un problème avec les limonène hydroxylases ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes métaboliques peuvent suggérer une dysfonction enzymatique."
}
},
{
"@type": "Question",
"name": "Y a-t-il des biomarqueurs associés aux limonène hydroxylases ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des métabolites spécifiques peuvent servir de biomarqueurs pour l'activité enzymatique."
}
},
{
"@type": "Question",
"name": "Comment les tests génétiques aident-ils au diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils identifient des mutations dans les gènes codant pour les limonène hydroxylases."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une déficience en limonène hydroxylases ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles métaboliques, des réactions allergiques ou des problèmes respiratoires."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon les individus ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'expression des symptômes peut varier en fonction de la génétique et de l'environnement."
}
},
{
"@type": "Question",
"name": "Peut-on observer des symptômes cutanés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des éruptions cutanées peuvent survenir en raison d'une hypersensibilité."
}
},
{
"@type": "Question",
"name": "Les symptômes respiratoires sont-ils fréquents ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme l'asthme peuvent être exacerbés par des métabolites du limonène."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques associés ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles neurologiques peuvent survenir, mais ils sont moins fréquents."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les troubles liés aux limonène hydroxylases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais éviter les allergènes peut aider à réduire les symptômes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures diététiques préventives ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et riche en nutriments peut soutenir la santé enzymatique."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils aider à la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent identifier les individus à risque et permettre une surveillance précoce."
}
},
{
"@type": "Question",
"name": "L'éducation sur les allergies est-elle importante ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, comprendre les allergies peut aider à éviter les déclencheurs et réduire les risques."
}
},
{
"@type": "Question",
"name": "Les environnements de travail peuvent-ils influencer la santé ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des environnements de travail exposant à des terpènes peuvent augmenter les risques."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les troubles liés aux limonène hydroxylases ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements symptomatiques et des modifications diététiques peuvent être recommandés."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est en recherche, mais pas encore largement disponible pour ces troubles."
}
},
{
"@type": "Question",
"name": "Des médicaments spécifiques existent-ils ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de médicaments spécifiques pour traiter ces déficiences."
}
},
{
"@type": "Question",
"name": "Comment la nutrition peut-elle aider ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en antioxydants peut soutenir la fonction enzymatique."
}
},
{
"@type": "Question",
"name": "Les traitements alternatifs sont-ils efficaces ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines thérapies alternatives peuvent aider à gérer les symptômes, mais peu de preuves."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une déficience en limonène hydroxylases ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications métaboliques et des réactions allergiques sévères peuvent se produire."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques à long terme ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des risques de maladies chroniques peuvent augmenter en raison de l'exposition continue."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent significativement impacter la qualité de vie des individus concernés."
}
},
{
"@type": "Question",
"name": "Des complications neurologiques sont-elles possibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, bien que rares, des complications neurologiques peuvent survenir dans certains cas."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les troubles enzymatiques ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents familiaux et des expositions environnementales peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de déficience ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines déficiences peuvent se manifester plus tard dans la vie."
}
},
{
"@type": "Question",
"name": "Les allergies augmentent-elles le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes allergiques peuvent être plus susceptibles de développer des troubles."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux à considérer ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des produits chimiques et à des terpènes peut être un facteur de risque."
}
},
{
"@type": "Question",
"name": "Le mode de vie joue-t-il un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain peut réduire le risque de complications liées aux enzymes."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 12/04/2025
Contenu vérifié selon les dernières recommandations médicales
2 publications dans cette catégorie
Affiliations :
College of Enology, Northwest A&F University, Yangling, Shaanxi, 712100, People's Republic of China.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Biotechnology, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 457 Zhongshan Road, Dalian, 116023, People's Republic of China.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
College of Enology, Northwest A&F University, Yangling, Shaanxi, 712100, People's Republic of China.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
College of Enology, Northwest A&F University, Yangling, Shaanxi, 712100, People's Republic of China. yangxb@nwafu.edu.cn.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Fasa University of Medical Sciences, Fasa, Iran. m.osanloo@fums.ac.ir.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Department of Energy Conversion and Storage, Faculty of Chemistry, Gdańsk University of Technology, G. Narutowicza 11/12, PL-80-233 Gdańsk, Poland.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Institute of Fluid-Flow Machinery, Polish Academy of Sciences, Fiszera 14 st., PL-80-231 Gdańsk, Poland.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
School of Food Engineering, Department of Food Science, University of Campinas, Campinas, Brazil.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California 92093, USA. vhgrassian@ucsd.edu.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry, University of California, Irvine, California 92697, USA. dtobias@uci.edu.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry, University of California, Irvine, California 92697, USA. dtobias@uci.edu.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California 92093, USA. vhgrassian@ucsd.edu.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Department of Chemical and Biological Engineering, Northwestern University, Evanston, IL, USA.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Department of Chemical and Biological Engineering, Northwestern University, Evanston, IL, USA.
Publications dans "Limonène hydroxylases" :
2 publications dans cette catégorie
Affiliations :
Department of Chemical and Biological Engineering, Northwestern University, Evanston, IL, USA.
Chemistry of Life Processes Institute, Northwestern University, Evanston, IL, USA.
Center for Synthetic Biology, Northwestern University, Evanston, IL, USA.
Robert H. Lurie Comprehensive Cancer Center, Simpson Querrey Institute Northwestern University, Chicago, IL, USA.
Simpson Querrey Institute Northwestern University, Chicago, IL, USA.
Publications dans "Limonène hydroxylases" :
1 publication dans cette catégorie
Affiliations :
DECHEMA-Forschungsinstitut, Industrial Biotechnology, Frankfurt am Main, Germany.
Faculty Biological Sciences, Goethe University Frankfurt, Frankfurt am Main, Germany.
Publications dans "Limonène hydroxylases" :
1 publication dans cette catégorie
Affiliations :
DECHEMA-Forschungsinstitut, Industrial Biotechnology, Frankfurt am Main, Germany.
Publications dans "Limonène hydroxylases" :
1 publication dans cette catégorie
Affiliations :
DECHEMA-Forschungsinstitut, Industrial Biotechnology, Frankfurt am Main, Germany.
Publications dans "Limonène hydroxylases" :
1 publication dans cette catégorie
Affiliations :
Faculty Biological Sciences, Goethe University Frankfurt, Frankfurt am Main, Germany.
Publications dans "Limonène hydroxylases" :
Multiple Sclerosis (MS) is a common immune-mediated disorder of the central nervous system that affects young adults and is characterized by demyelination and neurodegeneration. Recent studies have as...
Our incomplete understanding of the causes and pathways involved in the onset and progression of multiple sclerosis (MS) limits our ability to effectively treat this complex neurological disease. Rece...
Ocrelizumab is a humanised anti-CD20 monoclonal antibody developed for the treatment of multiple sclerosis (MS). It was approved by the Food and Drug Administration (FDA) in March 2017 for using in ad...
To assess the benefits, harms, and tolerability of ocrelizumab in people with RRMS and PPMS....
We searched MEDLINE, Embase, CENTRAL, and two trials registers on 8 October 2021. We screened reference lists, contacted experts, and contacted the main authors of studies....
All randomised controlled trials (RCTs) involving adults diagnosed with RRMS or PPMS according to the McDonald criteria, comparing ocrelizumab alone or associated with other medications, at the approv...
We used standard methodological procedures expected by Cochrane....
Four RCTs met our selection criteria. The overall population included 2551 participants; 1370 treated with ocrelizumab 600 mg and 1181 controls. Among the controls, 298 participants received placebo a...
For people with RRMS, ocrelizumab probably results in a large reduction in relapse rate and little to no difference in adverse events when compared with interferon beta-1a at 96 weeks (moderate-certai...
Multiple sclerosis (MS) is an autoimmune, T-cell-dependent, inflammatory, demyelinating disease of the central nervous system, with an unpredictable course. Current MS therapies focus on treating and ...
To evaluate the benefits and harms of alemtuzumab alone or associated with other treatments in people with any form of MS....
We used standard, extensive Cochrane search methods. The latest search date was 21 June 2022....
We included randomized controlled trials (RCTs) in adults with any subtype of MS comparing alemtuzumab alone or associated with other medications versus placebo; another active drug; or alemtuzumab in...
We used standard Cochrane methods. Our co-primary outcomes were 1. relapse-free survival, 2. sustained disease progression, and 3. number of participants experiencing at least one adverse event. Our s...
We included three RCTs (1713 participants) comparing intravenous alemtuzumab versus subcutaneous interferon beta-1a for relapsing-remitting MS. Participants were treatment-naive (two studies) or had e...
Compared with interferon beta-1a, alemtuzumab may improve relapse-free survival and sustained disease progression-free survival, and make little to no difference on the proportion of participants with...
The last thirty years have led to the introduction of treatments that reduce the frequency of relapses and slow the progression of multiple sclerosis. They must be prescribed early, chosen according t...
Tuberous sclerosis (TS) is a monogenic disorder which causes disabling neurological symptoms. Similarly, multiple sclerosis (MS) may result in disability, but in contrast, is diagnosed without genetic...
The objective of this study was to develop evidence-based recommendations on pregnancy management for persons with multiple sclerosis (MS)....
MS typically affects young women in their childbearing years. Increasing evidence is available to inform questions raised by MS patients and health professionals about pregnancy issues....
The French Group for Recommendations in Multiple Sclerosis (France4MS) reviewed PubMed and university databases (January 1975 through June 2021). The RAND/UCLA appropriateness method was developed to ...
A strong agreement was reached for all 104 proposed recommendations. They cover diverse topics, such as pregnancy planning, follow-up during pregnancy and postpartum, delivery routes, locoregional ana...
The 2022 recommendations of the French MS society should be helpful to harmonise counselling and treatment practice for pregnancy in persons with MS, allowing for better and individualised choices....
The factor that is most relevant and strongly associated with the clinical course of multiple sclerosis is chronological age. Very young patients exclusively have relapsing remitting disease, whereas ...
Changes in the immune system associated with ageing are known as immunosenescence. This is characterised by a decline in immune response, chronic inflammation and an increased risk of autoimmune disea...
Multiple sclerosis is a chronic inflammatory disease of the central nervous system, caused by an autoimmune reaction. Treatment options have largely increased over the years. In this article, we prese...